Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 261

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 261
---
 certain development services to Aptorum. In addition to the requirement of obtaining Aptorum shareholder approval, the closing of the merger is subject to the satisfaction or waiver of each of the other closing conditions set forth in the merger agreement and therefore, it is possible that the merger may not occur.

DiamiR has incurred net losses
in each year since its inception, including net losses of $743,235 and $614,405 for the years ended May 31, 2025 and 2024, respectively,
and $283,700 in the three months ended August 31, 2025. At August 31, 2025, DiamiR had an accumulated deficit of $6,106,271, primarily
due to operating expenses. DiamiR has devoted most of its financial resources to conducting studies on analysis of circulating organ-enriched
miRNA biomarkers and building its patent portfolio. DiamiR has not completed development of any product candidate and has therefore not
generated any revenues from product sales. Because of the numerous risks and uncertainties associated with the development of DiamiR’s
LDTs, DiamiR is unable to accurately predict the timing or amount of increased expenses or when, or if, DiamiR will be able to achieve
or maintain profitability. DiamiR expects to incur increased expenses as it conducts its clinical studies. DiamiR also expects an increase
in its expenses associated with creating additional infrastructure (including hiring additional personnel) to develop and launch CogniMIR and
support operations. As a result, DiamiR expects to continue to incur net losses and negative cash flows for the foreseeable future. These
net losses and negative cash flows have had, and will continue to have, an adverse effect on DiamiR’s stockholders’ equity
and working capital.

To date, DiamiR has financed
its operations through grant funding, including SBIR grants of approximately $9.7 million, an Alzheimer’s Drug Discovery Foundation
(ADDF) Award of $492,000, the sale of DiamiR equity securities to its founders in the total aggregate amount of $350,000 and borrowings
from its founders in the total aggregate amount of $1,075,000. In addition, while DiamiR has not earned revenue from its planned primary
operations, DiamiR has received fees for performing specified clinical and other testing services from commercial entities from time to
time. DiamiR has not, however, received such fees since March 202